Physician profile
Beverly Casinelli
NPI 1003452913
$935.42
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.11 · 2022: $444 · 2023: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $157.99 | 2022-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $133.05 | 2022-2023 | |
| Abbvie INC. | $117.64 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $88.04 | 2022 | |
| Lilly USA, LLC | $87.24 | 2022-2023 | Amyvid, Mounjaro |
| Exact Sciences Corporation | $73.64 | 2023 | Cologuard Collection Kit |
| Biogen, INC. | $46.03 | 2021-2022 | |
| Scynexis, INC. | $45.08 | 2022 | |
| Nestle Healthcare Nutrition INC. | $40.97 | 2022-2023 | |
| Cmp Pharma, INC. | $24.61 | 2023 | Carospir, Norliqva, Tadliq |
| Avanir Pharmaceuticals, INC. | $24.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.36 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $20.08 | 2023 | Dificid, Zinplava |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.45 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.08 | 2023 | Nuedexta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Casinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.